Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
Article first published online: 18 DEC 2002
Copyright © 2003 American Cancer Society
Volume 97, Issue 1, pages 114–120, 1 January 2003
How to Cite
Montillo, M., Tedeschi, A., O'Brien, S., Raimondo, F. D., Lerner, S., Ferrajoli, A., Morra, E. and Keating, M. J. (2003), Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer, 97: 114–120. doi: 10.1002/cncr.11000
- Issue published online: 18 DEC 2002
- Article first published online: 18 DEC 2002
- Manuscript Accepted: 29 JUL 2002
- Manuscript Revised: 19 JUL 2002
- Manuscript Received: 6 JUN 2002
One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL).
Twenty-nine patients with refractory or recurrent CLL or PLL received cladribine 4 mg/m2/day and cyclophosphamide 350 mg/m2/day (both administered intravenously) for 3 days every 4 weeks.
Eleven patients (38%), nine with CLL and two with PLL, had a response. The median duration of response was 12 months. Severe extrahematologic toxicity (National Cancer Institute Grade 3–4) occurred in two patients, consisting of skin rash in one patient and progressive multifocal leukoencephalopathy in the other. The most common form of hematologic toxicity was severe neutropenia, which developed after 25% of the 84 courses was administered. Severe thrombocytopenia and anemia developed after 12% and 7% of the courses, respectively, and five episodes of anemia were immunomediated. In addition, three major infections resulted in the death of one patient.
Although inferior to the combination fludarabine plus cyclophosphamide, this regimen showed interesting activity in patients with advanced CLL or PLL. Myelosuppression was the major dose-limiting toxic effect. Cancer 2003;97:114–20. © 2003 American Cancer Society.